The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation

International Journal of Radiation Oncology Biology Physics

Volumn 41, Issue 2, 1998, Pages 267-272

  Horwitz, Eric M ^a   Vicini, Frank A ^a   Ziaja, Ellen L ^a   Dmuchowski, Carl F ^a   Stromberg, Jannifer S ^a   Martinez, Alvaro A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Biochemical control; Prostate cancer; Prostate specific antigen; Radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0032076971     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00078-9     Document Type: Article

References (31)

1. Fukunaga-Johnson N., Sandler H.M., McLaughlin P.W., Strawderman M.S., Grijalva K.H., Kish K.E., Lichter A.S. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;311-317.
2. Hanks G.E., Lee W.R., Hanlon A.L., Hunt M., Kaplan E., Epstein B.E., Movsas B., Schultheiss T.E. Conformal technique for dose escalation for prostate cancer Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥ 10 ng/ml . Int. J. Radiat. Oncol. Biol. Phys. 35:1996;861-868.
3. Roach M. III, Meehan S., Kroll S., Weil M., Ryu J., Small E.J., Margolis L.W., Presti J., Carroll P.C., Phillips T.L. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J. Urol. 156:1996;1719-1723.
4. Forman J.D., Duclos M., Sharma R., Chuba P., Hart K., Yudelev M., Devi S., Court W., Shamsa F., Littrup P., Grignon D., Porter A., Maughan R. Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer Preliminary estimates of the therapeutic ratio . Int. J. Radiat. Oncol. Biol. Phys. 35:1996;259-266.
5. Russell K.J., Caplan R.J., Laramore G.E., Burnison C.M., Maor M.H., Taylor M.E., Zink S., Davis L.W., Griffin T.W. Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer Results of a randomized prospective trial . Int. J. Radiat. Oncol. Biol. Phys. 28:1994;47-54.
6. Stromberg J.S., Martinez A.A., Gonzalez J.A., Edmundson G.K., Ohanian N., Vicini F.A., Hollander J.B., Gustafson G.S., Spencer W.F., Yan D., Brabbins D.S. Ultrasound guided high dose rate conformal brachytherapy boost in prostate cancer Treatment description and preliminary results of Phase I/II clinical trial . Int. J. Radiat. Oncol. Biol. Phys. 33:1995;161-171.
7. Stromberg J.S., Martinez A.A., Horwitz E.M., Gustafson G.S., Gonzalez J.A., Spencer W.F., Brabbins D.S., Dmuchchowski C.F., Hollander J.B., Vicini F.A. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer Superior prostate specific antigen response compared to external beam treatment . Cancer J. Sci. Am. 3:1997;346-352.
8. Hanks G.E. External beam radiation treatment for prostate cancer Still the gold standard . Oncology. 6:1992;79-89.
9. Leibel S.A., Zelefsky M.J., Kutcher G.J., Burman C.M., Kelson S., Fuks Z. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate Interim report of a phase I dose-escalation study . J. Urol. 152:1994;1792-1798.
10. McLaughlin P.W., Sandler H.M., Jiroutek M.R. Prostate-specific antigen following prostate radiotherapy How low can you go? J. Clin. Oncol. 14:1996;2889-2892.
11. Prostate. Beahrs O.H., Henson D.E., Hutter R.V.P., Kennedy B.J. Manual for the staging of cancer. 1992;181-186 Lippincott, Philadelphia.
12. Horwitz E.M., Vicini F.A., Ziaja E.L., Gonzalez J., Dmuchowski C.F., Stromberg J.S., Brabbins D.S., Hollander J., Chen P.Y., Martinez A.A. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;565-571.
13. Consensus statement Guidelines for PSA following radiation therapy . Int. J. Radiat. Oncol. Biol. Phys. 37:1997;1035-1041.
14. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
15. Cox D.R. Regression models and life tables. J. Royal Stat. Soc. 34:1972;187-220.
16. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Instit. 22:1959;719-748.
17. Lehmann E.L. Non-parametrics Statistical methods based on ranks . 1975;Holden-Day, San Francisco.
18. Catalona W.J., Smith D.S., Ratcliff T.L., Dodds K.M., Coplen D.E., Yuen J.J., Petros J.A., Andriole G.L. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324:1991;1156-1161.
19. Woolf S.H. Screening for prostate cancer with prostate-specific antigen An examination of the evidence . N. Engl. J. Med. 333:1995;1401-1405.
20. Hanks G.E., Lee W.R., Schultheiss T.E. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J. Urol. 154:1995;456-459.
21. Kuban D.A., El-Mahdi A.M., Schellhammer P.F. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;307-316.
22. Lee W.R., Hanks G.E., Schultheiss T.E., Corn B.W., Hunt M.A. Localized prostate cancer treated by external-beam radiotherapy alone Serum prostate-specific antigen-driven outcome analysis . J. Clin. Oncol. 13:1995;464-469.
23. Zagars G.K., Pollack A. Radiation therapy for T1 and T2 prostate cancer Prostate-specific antigen and disease outcome . Urology. 45:1995;476-483.
24. Zagars G.K., Pollack A., Kavadi V.S., von Eschenbach A.C. Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;293-306.
25. Zietman A.L., Coen J.J., Dallow K.C., Shipley W.U. The treatment of prostate cancer by conventional radiation therapy An analysis of long-term outcome . Int. J. Radiat. Oncol. Biol. Phys. 32:1995;287-292.
26. Critz F.A., Levinson K., Williams W.H., Holladay D.A. Prostate-specific antigen nadir The optimum level after irradiation for prostate cancer . J. Clin. Oncol. 14:1996;2893-2900.
27. Crook J.M., Bahadur Y.A., Bociek R.G., Perry G.A., Robertson S.J., Esche B.A. Radiotherapy for localized prostate carcinoma The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome assessed by systematic biopsy and serum prostate specific antigen . Cancer. 79:1997;81-89.
28. Lee W.R., Hanlon A.L., Hanks G.E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer The relationship between nadir level and disease-free survival . J. Urol. 156:1996;450-453.
29. Zietman A.L., Tibbs M.K., Dallow K.C., Smith C.T., Althausen A.F., Zlotecki R.A., Shipley W.U. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother. Oncol. 40:1996;151-162.
30. Leibel S.A., Scott C.B., Mohiuddin M., Marcial V.A., Coia L.R., Davis L.W., Fuks Z. The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck Results of an analysis from the RTOG head and neck database . Int. J. Radiat. Oncol. Biol. Phys. 21:1991;549-556.
31. 125I implantation . Int. J. Radiat. Oncol. Biol. Phys. 21:1991;537-547.